Shares of Eli Lilly (LLY) are up $11.11, or about 2%, to $709.29 in pre-market trading while those of Novo Nordisk (NVO) trading in New York are also up 2% to $54.83 after potential weight loss drug competitor Viking Therapeutics (VKTX) announced top-line results from the company’s Phase 2 clinical trial of the oral tablet formulation of VK2735.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LLY:
- Analysts Rally Behind Eli Lilly (LLY) Stock After 24% Slide
- Morning News Wrap-Up: Monday’s Biggest Stock Market Stories
- Eli Lilly (LLY) Signs $1.3 Billion Deal with Superluminal to Discover Future Drugs Using AI
- Novo Nordisk (NVO) Stock Gains as Wegovy Drug Gets FDA Nod for Liver Disease
- Eli Lilly downgraded to Neutral from Outperform at Daiwa